183 related articles for article (PubMed ID: 23266353)
1. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.
McIntyre JB; Wu JS; Craighead PS; Phan T; Köbel M; Lees-Miller SP; Ghatage P; Magliocco AM; Doll CM
Gynecol Oncol; 2013 Mar; 128(3):409-14. PubMed ID: 23266353
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
Martell K; McIntyre JB; Kornaga EN; Chan AMY; Phan T; Köbel M; Enwere EK; Dean ML; Ghatage P; Lees-Miller SP; Doll CM
Gynecol Oncol; 2020 Sep; 158(3):776-784. PubMed ID: 32653099
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Shigaki H; Baba Y; Watanabe M; Murata A; Ishimoto T; Iwatsuki M; Iwagami S; Nosho K; Baba H
Clin Cancer Res; 2013 May; 19(9):2451-9. PubMed ID: 23532889
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
5. The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis.
Doll CM; Aquino-Parsons C; Pintilie M; Klimowicz AC; Petrillo SK; Milosevic M; Craighead PS; Clarke B; Lees-Miller SP; Fyles AW; Magliocco AM
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):721-7. PubMed ID: 22836058
[TBL] [Abstract][Full Text] [Related]
6. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
[TBL] [Abstract][Full Text] [Related]
7. Equivalent survival in patients with advanced stage IB-II and III-IVA cervical cancer treated by adjuvant surgery following chemoradiotherapy.
Carcopino X; Houvenaeghel G; Buttarelli M; Esterni B; Tallet A; Goncalves A; Jacquemier J
Eur J Surg Oncol; 2008 May; 34(5):569-75. PubMed ID: 17531428
[TBL] [Abstract][Full Text] [Related]
8. Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy.
Wang J; Chai YL; Wang T; Liu JH; Dai PG; Liu Z
Exp Mol Pathol; 2015 Jun; 98(3):407-10. PubMed ID: 25773678
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.
Lachkar B; Minaguchi T; Akiyama A; Liu S; Zhang S; Xu C; Shikama A; Tasaka N; Sakurai M; Nakao S; Ochi H; Yoshikawa H; Satoh T
Medicine (Baltimore); 2018 Aug; 97(31):e11392. PubMed ID: 30075505
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and Prognostic Significance of PIK3CA Mutation and CNV Status and Phosphorylated AKT Expression in Patients With Cervical Cancer Treated With Primary Surgery.
Martell K; McIntyre JB; Abedin T; Kornaga EN; Chan AMY; Enwere E; Köbel M; Dean ML; Phan T; Ghatage P; Lees-Miller SP; Doll CM
Int J Gynecol Pathol; 2024 Mar; 43(2):158-170. PubMed ID: 37668363
[TBL] [Abstract][Full Text] [Related]
12. Outcomes and toxicities for the treatment of stage IVB cervical cancer.
Hwang JH; Lim MC; Seo SS; Kang S; Park SY; Kim JY
Arch Gynecol Obstet; 2012 Jun; 285(6):1685-93. PubMed ID: 22173823
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level.
Lee YY; Choi CH; Sung CO; Do IG; Huh S; Song T; Kim MK; Kim HJ; Kim TJ; Lee JW; Kim BG; Bae DS
Gynecol Oncol; 2012 Jan; 124(1):92-7. PubMed ID: 22014631
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study.
Blohmer JU; Paepke S; Sehouli J; Boehmer D; Kolben M; Würschmidt F; Petry KU; Kimmig R; Elling D; Thomssen C; von Minckwitz G; Möbus V; Hinke A; Kümmel S; Budach V; Lichtenegger W; Schmid P
J Clin Oncol; 2011 Oct; 29(28):3791-7. PubMed ID: 21860000
[TBL] [Abstract][Full Text] [Related]
15. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
Huang YT; Wang CC; Tsai CS; Lai CH; Chang TC; Chou HH; Lee SP; Hong JH
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):420-7. PubMed ID: 22365621
[TBL] [Abstract][Full Text] [Related]
16. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
Hafner C; Landthaler M; Vogt T
Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer.
Kato S; Iida S; Higuchi T; Ishikawa T; Takagi Y; Yasuno M; Enomoto M; Uetake H; Sugihara K
Int J Cancer; 2007 Oct; 121(8):1771-8. PubMed ID: 17590872
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
Lim A; Sia S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
[TBL] [Abstract][Full Text] [Related]
19. Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients?
Lin CH; Lu YS; Huang CS; Kuo KT; Wang CC; You SL; Lin PH; Chang DY; Kuo WH; Chang KJ; Cheng AL
J Clin Pathol; 2011 Sep; 64(9):781-7. PubMed ID: 21642658
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy.
Gadducci A; Teti G; Barsotti C; Tana R; Fanucchi A; Orlandini C; Fabrini MG; Genazzani AR
Anticancer Res; 2010 Jan; 30(1):201-8. PubMed ID: 20150636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
